Eli Lilly reported that 60% of patients using tirzepatide achieved normal blood sugar levels compared to 24% using standard GLP-1 therapies. The SURPASS-EARLY trial, funded by Lilly, tracked nearly 800 adults with type 2 diabetes over two years.

Tirzepatide Outperforms Standard GLP-1 Competitors